Background: Glaucoma is a chronic progressive optic neuropathy requiring lifelong monitoring and treatment. Traditional face-to-face clinic visits can pose challenges including long waiting times, transportation difficulties, and increasing service demands. Tele-glaucoma and virtual glaucoma clinics have emerged as innovative service delivery models aimed at improving access, efficiency, and patient satisfaction. Purpose: To synthesize and critically appraise evidence on patient satisfaction and experiences with tele‑glaucoma and virtual glaucoma clinic models, and to identify factors influencing their acceptability. Methods: A systematic search of PubMed, Scopus, and Web of Science was conducted using predefined terms related to tele‑glaucoma, virtual eye care, and patient‑reported experiences in glaucoma. Reference lists of included articles were hand‑searched. Eligible studies evaluated satisfaction, perceptions, or experiences of adults with glaucoma, ocular hypertension, or glaucoma‑suspect status receiving care through tele‑glaucoma, virtual clinics, remote monitoring, shared medical appointments, or related digital interventions. Two reviewers independently screened studies, extracted data, and assessed risk of bias using design‑appropriate tools. Results: Of 225 records identified, seven primary studies specifically assessed tele‑glaucoma or virtual glaucoma services within a broader review of 27 studies on glaucoma care satisfaction. All were conducted in high‑income settings (United Kingdom, United States, Finland) and were mainly cross‑sectional surveys, clinical audits, or pilot projects. Interventions included full virtual clinics with technician‑led testing and asynchronous specialist review, small‑scale tele‑glaucoma pilots, shared medical appointments, educational interventions, and appointment/SMS reminder systems. Across studies, satisfaction with tele‑glaucoma and virtual models was high (typically >85%), with many patients rating care as equivalent or superior to traditional clinics and expressing willingness to reuse or recommend services. Key positive drivers were convenience, structured scheduling, confidence in trained non‑physician staff, and clear specialist oversight. Negative themes included inadequate explanation of results and prognosis, limited direct physician interaction, and communication concerns. Conclusions: Tele‑glaucoma and virtual glaucoma clinics are generally well accepted and can achieve satisfaction comparable to in‑person care when supported by robust education, clear communication pathways, and reliable technician‑led data collection with visible specialist involvement. Further research using standardized outcome measures and more diverse settings is needed to optimize patient‑centred tele‑glaucoma models.

Mango (Mangifera indica) and peach (Prunus persica) juices are highly perishable, requiring innovative preservation methods to enhance their nutritional value and shelf life. This study evaluates the effect of single-cell protein (SCP) derived from Saccharomyces cerevisiae on the composition and stability of these juices. SCP fortification significantly increased protein content (mango: 0.47% to 0.91%, peach: 0.42% to 0.85%) and fiber (mango: 0.31% to 0.75%, peach: 0.30% to 0.71%), while reducing fat content. Antioxidant capacity improved, with flavonoid content rising (mango: 36.57 to 52.78 mg QE/mL, peach: 34.25 to 48.91 mg QE/mL) and DPPH activity increasing (mango: 39.52% to 62.37%, peach: 37.46% to 59.28%). Ascorbic acid levels, mineral content (calcium, magnesium), and superoxide dismutase activity also showed notable enhancements. SCP treatment slightly increased pH and viscosity, contributing to juice stability. Sensory evaluation confirmed improved color, aroma, and taste, enhancing consumer acceptability. These findings highlight SCP as a sustainable, functional additive for improving the nutritional quality and shelf life of fruit juices, offering potential applications in the food industry.

Population growth, habitat destruction, climate change, and new diseases are all threats to the world's fisheries and aquaculture. Traditional selective breeding has achieved success, but has some drawbacks such as long breeding cycles, polygenetic nature of traits, and limited genetic diversity in closed populations. The potential of CRISPR-Cas genome editing is a recent technology that has been used in zebrafish since 2013, and is now revolutionizing the genetic improvement of Atlantic salmon, Nile tilapia, rainbow trout, channel catfish, grass carp, and others. This precision has been further improved by advanced technologies such as base editors, prime editors, CRISPRa, and CRISPRi. Applications include growth enhancement through myostatin disruption; increased disease resistance, reproductive efficiency, flesh quality and thermal/osmotic stress tolerance. These tackle key production bottlenecks, while contributing to lower use of antibiotics, lower environmental footprint and climate-resilient systems based on the UN SDGs. Even with these challenges, there are significant issues off-target effects, mosaicism, regulatory issues, public acceptance and polygenetic traits. Now, new technologies like artificial intelligence-driven design, multi-omics, multiplex editing, and epigenome editing provide answers. To be fully commercialised, regulatory harmonisation and transparent communication are paramount.